【レポートの概要（一部）】
1. Report Summary
1.1 Leading Contract Manufacturing Organisations (CMOs) Review
1.2 Leading CMOs – Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers Information
1.5 Main Questions This Report Answers
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQs)
1.9 Some Related Reports
1.10 About Visiongain
2. Introduction to Pharmaceutical Contract Manufacturing, 2014
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2013
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2014-2024
2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2014-2024
2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2014-2024
2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2014-2024
2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2014?
3. Leading European Contract Manufacturing Organisations (CMOs), 2014
3.1 Lonza
3.1.1 Lonza Is a Leader in Biologics Manufacturing
3.1.2 Lonza Contract Manufacturing and Development: Declining Revenue, but Increased Efficiency, 2009-2013
3.1.3 Investing in Advanced Biological Drug Sectors
3.1.4 The Promise of Antibody-Drug Conjugates (ADCs)
3.1.5 Lonza and Regenerative Medicine
3.1.6 Lonza: SWOT Analysis 2014-2024
3.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2014-2024
3.1.8 Lonza: Company Insight
3.2 Evonik Degussa
3.2.1 Investing in API and Drug Delivery Services
3.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2009-2013
3.2.3 Evonik Is a HPAPI Specialist
3.2.4 Evonik Continues to Grow Across All Segments
3.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
3.2.6 Evonik Degussa: Revenue Forecast 2014-2024
3.3 Royal DSM
3.3.1 Marginal Revenue Growth and Rapidly Declining Operating Profit in Pharma Manufacturing 2009-2013
3.3.2 DSM Pharmaceuticals Products: Manufacturing Services 2009-2013
3.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
3.3.4 DPx Holdings: A New Leader in the CMO Market
3.3.5 Investing in Biopharma Manufacturing
3.3.6 Expanding API Manufacturing
3.3.7 Generics and Biologics Are an Opportunity for Growth, 2014-2024
3.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2014-2024
3.4 Boehringer Ingelheim Contract Manufacturing
3.4.1 Expanding Biopharmaceuticals Manufacturing Services in China
3.4.2 Production Through to Fill and Finished Biopharmaceuticals
3.4.3 A Track Record of Production for 28 Biopharma Products
3.4.4 Declining Revenue from Contract Manufacturing, 2009-2013
3.4.5 Pulling Out of Small Molecule API Manufacturing
3.4.6 Expanding through New Services
3.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2014-2024
3.4.8 Boehringer Ingelheim: Revenue Forecast 2014-2024
3.4.9 Boehringer Ingelheim Biopharmaceuticals: Company Insight
3.5 Fareva
3.5.1 Fareva Has 35 Years’ Manufacturing Experience
3.5.2 Revenue Growth through Acquisitions: 2009-2013
3.5.3 Fareva SWOT Analysis: 2014-2024
3.5.4 Fareva Revenue Forecast: 2014-2024
3.6 Aenova Group
3.6.1 Acquisition of Haupt Creates European CMO Goliath
3.6.2 Aenova’s Ever Expanding Manufacturing Capacity
3.6.3 Aenova’s Revenue 2009-2013: Organic Growth and Acquisitions
3.6.4 Haupt Pharma Acquisition: Revenue Growth 2009-2013
3.6.5 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2014-2024
3.6.6 Becoming a Leading Contract Manufacturer: Aenova Revenue and Operation Profit Forecast 2014-2024
3.7 Famar
3.7.1 Famar Is an Expert in Lyophilisation
3.7.2 Sustained Growth in Famar’s Revenue: 2009-2013
3.7.3 Expanding European Operations
3.7.4 Further Site Acquisitions Are an Opportunity for Growth 2014-2024
3.7.5 How Will Famar Perform 2014-2024?
3.8 Vetter Pharma
3.8.1 Vetter is an Injectable Manufacturing Specialist
3.8.2 Rapidly Growing Revenue in the US and Germany: 2009-2013
3.8.3 Services, Collaborations and Differentiating Factors
3.8.4 Biologics Are an Opportunity for Growth for Vetter 2014-2024
3.8.5 Vetter Outlook: Revenue Forecast 2014-2024
3.9 Almac Group
3.9.1 Almac’s Manufacturing Services
3.9.2 Almac Outpaces the Market: 2009-2013
3.9.3 Almac Adds Capacity in the UK and US
3.9.4 New Services Added 2012-2014
3.9.5 Almac Group: Contract Manufacturing Market Outlook 2014-2024
3.9.6 How Will Almac Group Perform 2014-2024?
3.10 Delpharm
3.10.1 Finished Dosage Form Manufacturing for Developed Markets
3.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2009-2013
3.10.3 Delpharm: Outlook and Prospects for Growth 2014-2024
3.10.4 Generics Will Drive Revenue Growth for Delpharm 2014-2024
3.11 Siegfried
3.11.1 Expanding Siegfried’s Manufacturing Footprint
3.11.2 Siegfried: Financial Performance 2009-2013
3.11.3 Expanding High Potency API Capabilities
3.11.4 Expanding Into China 2013-2014
3.11.5 Siegfried’s Characteristics Within the Contract Manufacturing Market: SWOT Analysis 2014-2024
3.11.6 Continued Revenue Growth for Siegfried 2014-2024
3.12 Corden Pharmaceutical
3.12.1 CordenPharma Has Grown through Acquisitions
3.12.2 Corden Pharmaceutical: SWOT Analysis 2014-2024
3.13 Recipharm
3.13.1 Contract Development and Manufacturing Services
3.13.2 Recipharm: Financial Performance 2009-2013
3.13.3 Recipharm Invests in Facility Expansion
3.13.4 Recipharm: Opportunities for Growth 2014-2024
3.13.5 Outlook for Recipharm: Revenue Forecast 2014-2024
3.13.6 Recipharm: Company Insight
3.14 Aesica Pharmaceuticals
3.14.1 Aesica Manufactures APIs and Finished Dosage Forms
3.14.2 Acquisitions Drive Revenue Growth But Operational Margins Have Declined, 2009-2013
3.14.3 Partnering with Academia for Innovative Solutions
3.14.4 Growth through Acquisitions and Internal Expansion
3.14.5 Aesica: Opportunities for Expansion 2014-2024
3.14.6 Forecast Aesica Financial Performance, 2014-2024
4. Other Leading Developed-Market CMOs, 2014
4.1 Catalent Pharma Solutions Is the World’s Largest CMO
4.1.1 Catalent: Manufacturing Services and Capabilities
4.1.2 Divisional Segmentation – Breaking Down Catalent’s Service
4.1.3 Revenue Growth with Improved Operational Margins: Catalent Pharma’s Performance, 2009-2013
4.1.4 Sustained Grow in Oral Products and Development Services: Catalent Pharma’s Divisional Performance, 2009-2013
4.1.5 Catalent Is Expanding its Oral Technologies Division
4.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity
4.1.7 Adding New Early-Stage Development Services
4.1.8 Expansion in Japan – Growth Prospects for Catalent
4.1.9 New Business Contracts 2013-2014
4.1.10 Catalent: Opportunities for Growth 2014-2024
4.1.11 Catalent: Mild Growth in Revenue and Operating Profit 2014-2024
4.2 Patheon – FDF Manufacturer and Drug Development Services
4.2.1 Patheon – Global leader in Pharmaceutical Development Services
4.2.2 Contract Manufacturing Services at Patheon
4.2.3 Steady Revenue Growth 2009-2013
4.2.4 Formation of DPx Holdings
4.2.5 Adding New Formulations and Formulation Development Services
4.2.6 Reassessing Manufacturing Capacity
4.2.7 Patheon: SWOT Analysis 2014-2024
4.2.8 Patheon: Contract Manufacturing Revenue Forecast 2014-2024
4.2.9 Patheon: Company Insight
4.3 Baxter BioPharma Solutions
4.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
4.3.2 Historic Revenue Performance 2009-2013
4.3.3 Baxter BioPharma SWOT Analysis 2014-2024
4.3.4 Baxter BioPharma Revenue Forecast 2014-2024
4.4 Nipro Corporation: Japan’s Leading CMO
4.4.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
4.4.2 Nipro: Exceptional Growth in Revenue and Operating Profits 2009-2013
4.4.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2014-2024
4.4.4 Nipro Revenue and Profitability Forecast 2014-2014
4.5 AbbVie Contract Manufacturing
4.5.1 AbbVie Offers Full-Service Contract Manufacturing
4.5.2 Expanding and Adding New Services: 2013-2014
4.5.3 AbbVie Contract Manufacturing: Revenue 2011-2013
4.5.4 Biologics and HPAPIs Are an Opportunity for Growth 2014-2024
4.5.5 AbbVie Contract Manufacturing Revenue Forecast 2014-2024
4.5.6 AbbVie Contract Manufacturing: Company Insight
4.6 Daito Pharmaceutical
4.6.1 Daito Has a Portfolio of More than 30 APIs
4.6.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2009-2013
4.6.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis 2014-2024
4.6.4 Sustained Growth in Revenue and Operating Profit for Daito, 2014-2024
4.7 Pfizer CentreSource
4.7.1 Pfizer CentreSource: Historic Revenue Performance, 2009-2013
4.7.2 Will Pfizer Divest CentreSource?
4.7.3 Outlook for CentreSource: Revenue Forecast 2014-2024
5. Leading Developed Market API Manufacturers, 2014
5.1 Teva API
5.1.1 API Manufacturing Services
5.1.2 Teva API: Financial Performance 2009-2013
5.1.3 Building a Footprint in Mexico, India and China
5.1.4 Teva API: SWOT Analysis 2014-2024
5.1.5 Outlook for Teva API: Revenue Forecast 2014-2024
5.2 Esteve Química
5.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
5.2.2 Investing to Expand 2004-2013
5.2.3 Esteve Química: SWOT Analysis 2014-2024
5.3 Euticals
5.3.1 Euticals Manufactures More than 200 APIs
5.3.2 Acquisitions Drive Growth 2009-2013
5.3.3 Adding Capacity for Finished Dosage Forms
5.3.4 Asian Expansion Is an Opportunity for Growth 2014-2024
5.3.5 Euticals: Revenue Forecast 2014-2024
6. Leading Chinese Pharmaceutical Contract Manufacturers, 2014
6.1 Zhejiang Hisun Pharmaceutical
6.1.1 API Manufacturing for Markets Worldwide
6.1.2 Zhejiang Hisun’s Rapid Growth in API Revenue Grows, 2009-2013
6.1.3 Moving Into International Drug Marketing
6.1.4 Zhejiang Hisun: Opportunities for Growth 2014-2024
6.1.5 Zhejiang Hisun: Strong API Revenue Growth 2014-2024
6.2 Zhejiang Huahai Pharmaceuticals
6.2.1 Zhejiang Huahai Is a Market Leader Within the Antihypertensive API Market
6.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2009-2013
6.2.3 Expanding in the US Generic Drugs Market
6.2.4 Zhejiang Huahai: SWOT Analysis, 2014
6.2.5 Zhejiang Huahai: Revenue Forecast, 2014-2024
6.3 Shandong Xinhua Pharmaceutical
6.3.1 Experience in APIs and Finished Dosage Forms
6.3.2 Shandong Xinhua: Strong Revenue Growth 2009-2013
6.3.3 Growing through Joint Ventures
6.3.4 Looking to Expand in the US and EU 2014-2024
6.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2014-2024
7. Leading Indian Pharmaceutical Contract Manufacturers, 2014
7.1 Aurobindo Pharma
7.1.1 API Manufacturing Services
7.1.2 Aurobindo Pharma: Steady Revenue Growth 2009-2013
7.1.3 Aurobindo Expanding Outside of Antibacterials
7.1.4 Aurobindo: Opportunities for Expansion 2014-2024
7.1.5 How Will Aurobindo’s Contract Manufacturing Division Perform 2014-2024?
7.2 Divis Laboratories
7.2.1 Divis Laboratories and the Contract Manufacturing Industry
7.2.2 Divis Laboratories: The Fastest Growing CMO 2009-2013
7.2.3 Divis Laboratories: API Manufacturing Outlook 2014-2024
7.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2014-2024
7.3 Dr. Reddy’s Laboratories
7.3.1 API and FDF Manufacturing Services
7.3.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2009-2013
7.3.3 Advancing in Complex Drug Manufacturing
7.3.4 Expanding in the European Manufacturing Market
7.3.5 Dr. Reddy’s PSAI Division: Revenue Forecast 2014-2024
8. Conclusions to Our Study
8.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
8.2 Strategies for Growth: Prospects for Leading CMOs, 2014-2024
8.3 High Demand for Biopharmaceutical Manufacturing Services
8.4 Investing in Novel Technologies
8.5 Outlook for API Manufacturers
【レポート販売概要】
■ タイトル：医薬品有力企業シリーズ：主要医薬品製造受託機関(CMO)分析■ 英文：Pharma Leader Series : Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024
■ 発行日：2014年9月
■ 調査会社：visiongain
■ 商品コード：VISION411062
■ 調査対象地域：グローバル
- 世界のヘリコプター・シミュレータ市場：Global Helicopter Simulators Market 2014-2018TechNavio's analysts forecast the Global Helicopter Simulators market to grow at a CAGR of 2.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the growing demand for commercial aircrafts. The Global Helicopter Simulators market has also been witnessing the increasing demand for full flight simulators. However, the high initial cost of simulators cou …
- UC2.0（ユニファイドコミュニケーション）SIの世界市場2015-2019About UC 2.0 services Enterprises focus on integrating their real-time communication tools such as text messaging, video conferencing, voice messaging, and other mobility features in their products to leverage the advancements in communication technology. The widespread implementation of unified communication has made business communication fast and has improved the business productivity. Usage of …
- 自動販売機の世界市場2019-2023About this market The rise in adoption of intelligent vending machines to propel growth in the market. Unlike conventional vending machines that just dispense products, intelligent vending machines have advanced features such as operations and inventory management, customer analytics, transaction management, software and platform management, and digital advertising and content management systems. …
- 携帯電話用ターボ充電器の世界市場2017-2021About Mobile Phone Turbo Chargers The increasing Internet penetration worldwide, coupled with the increasing unit shipments of smartphones and tablets, has led to a high demand for mobile applications. The increasing penetration of LTE and 3G services across the globe have made consumers spoilt for choice. Using multiple apps on a device considerably increases the device power consumption, and use …
- 2-メルカプトベンゾイミダゾールの世界市場2-Mercaptobenzimidazole (CAS 583-39-1) Market Research Report 2014 presents comprehensive data on 2-mercaptobenzimidazole markets globally and regionally (Europe, Asia, North America etc.) The report includes 2-mercaptobenzimidazole description, covers its application areas and related patterns. It overviews 2-mercaptobenzimidazole market, names 2-mercaptobenzimidazole producers and indicates its …
- 中国のバイオ燃料市場：バイオエタノール、バイオディーゼル、バイオジェット燃料About biofuels market in China The continuous growth in the population has led to increased power consumption in the production and transportation sectors. As a result, there is a rise in the level of pollution and GHG. China accounted for 23% of the global energy consumption in the year 2014 according to BP. Over-dependence on coal and oil for power generation and volatile oil prices have increas …
- Enteric Diseases in Italy 2014: Market Outlook and Emerging OpportunitiesAbout This ReportThis new 322-page report from Venture Planning Group presents detailed analysis of the Italian Enteric Diseases market, including sales forecasts and supplier shares for Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio and Yersinia. The report provides test volume and sales projections for Hospitals and Commercial/Priv …
- NFV（ネットワーク機能の仮想化）の世界市場：ビジネス事例、市場分析、予測Network Functions Virtualization (NFV) is a telecom led initiative that aims to utilize standard IT virtualization technology to consolidate many telecom network equipment types onto industry standard high volume servers, switches and storage. NFV involves implementing network functions in software that can run on a range of industry standard server hardware, and that can be moved to, or instantia …
- 醸造用酵素の世界市場予測（～2023年）：アミラーゼ、β-グルカナーゼ、プロテアーゼ、キシラナーゼ、ALDC、ペクチナーゼThe brewing enzymes market is estimated at USD 352.1 million in 2018. It is projected to reach USD 484.7 million by 2023, at a CAGR of 6.6% from 2018, in terms of value. The use of enzymes has become increasingly important in the brewing industry, as they accelerate the chemical reaction without a change in their own structure. To enhance the brewing process, commercial exogenous enzymes are used …
- 契約ライフサイクル管理（CLM）の世界市場2015-2019About contract life cycle management (CLM) Traditionally, contracts were documented on paper and presented for any revisions or amendments till the final version was prepared. Lawyers used to review the contracts manually, which was a time consuming and error prone process. With evolution in technology, companies started managing contracts via the electronic media. However, the electronic format o …
- ケーブルアセンブリの世界市場2015-2019About Cable Assembly Cable assembly is a collection of wires and cables banded into a single unit. It is used to connect various types of systems and equipment to carry out the desired operation. Cable assembly is used in operations across both process and discrete industries. Cable assemblies based on their applications include multi-conductor, coaxial, wire and cable harness, complex military, f …
- せん断ビーム型ロードセルの世界市場展望2017-20276According to Stratistics MRC, the Global Shear Beam Load Cells Market is accounted for $5.04 billion in 2017 and is expected to reach $8.67 billion by 2026 growing at a CAGR of 6.2% during the forecast period. Increasing demand for load cells from industries such as healthcare and rising investments in industrial automation technologies are some of the factors fuelling market growth. However, cont …
- ATMスライドレールの世界市場2016-2020About ATM Slide Rails Slide rails have been an important part of the ATM hardware. They find their application in the pulling out the different mobile components of the ATM hardware components such as cash dispenser unit (CDU), cartridges, error box, deposit box, and also the front panel of the ATM. ATM slide rails come under the business head of the mechanical unit in most of the vendors as these …
- インドのプレハブ建築（システム建築）市場2016-2020About the Pre-Engineered Building (PEB) Market in India The construction market in India has expanded significantly after the economic liberalization in the 1990s. The introduction of PEBs has improved the construction market in India. Additionally, with the increased approval of FDIs and the Make in India campaign initiated by the government of India, there has been a rise in the demand for infra …
- 脳脊髄炎（Encephalomyelitis）：グローバル臨床試験動向（2014年上半期）Encephalomyelitis Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Encephalomyelitis Global Clinical Trials Review, H1, 2014" provides data on the Encephalomyelitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Encephalomyelitis. It includes an overview of the trial numbers and their recruitment s …
